Related Experiment Video
Updated: Jul 17, 2026
Analyzing the Functions of Mast Cells In Vivo Using 'Mast Cell Knock-in' Mice
Published on: May 27, 2015
[Report of six cases with mast cell leukemia and a literature review]
1Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, the First Affiliated Hospital of Soochow University, Suzhou 215006, China.
Insights
Mast cell leukemia (MCL) is a rare, aggressive blood cancer. This study of six patients highlights its varied symptoms, poor prognosis, and the urgent need for better understanding and treatment strategies.
Area of Science:
- Hematology
- Oncology
- Rare Diseases
Background:
- Mast cell leukemia (MCL) is an aggressive and rare subtype of systemic mastocytosis.
- Clinical and laboratory data of MCL patients often present with heterogeneity.
- Understanding MCL's characteristics is crucial for improving patient outcomes.
Purpose of the Study:
- To retrospectively analyze the clinical and laboratory data of MCL patients.
- To describe the clinical presentations, diagnostic findings, and treatment responses in MCL.
- To evaluate the prognosis and identify areas for future research in MCL.
Main Methods:
- Retrospective analysis of clinical and laboratory data from six MCL patients.
- Data collected from October 2021 to February 2023 at the First Affiliated Hospital of Soochow University.
- Inclusion criteria: acute MCL with at least one C-finding.
Main Results:
- Common presentations included hypoalbuminemia, fatigue, fever, and osteolytic lesions.
- Immunophenotyping showed positivity for CD117, CD30, CD25, and CD2 in most patients.
- Gene mutations were detected in 4/6 cases; treatment responses were variable, with a poor overall outcome.
Conclusions:
- Mast cell leukemia is a rare systemic mastocytosis subtype with a heterogeneous clinical course and poor prognosis.
- The study underscores the need for a deeper understanding of MCL's clinical characteristics, treatment options, and prognostic factors.
- Further research is essential to develop more effective therapeutic strategies for mast cell leukemia.
Abstract:
From October 2021 to February 2023, we retrospectively analyzed the clinical and laboratory data of six patients (three male and three female, median age: 54 years, age range: 29-73 years) with mast cell leukemia (MCL) diagnosed in the First Affiliated Hospital of Soochow University (The Mastocytosis Collaborative Network of China). All patients had acute MCL, with at least one C-finding present. The main clinical presentations were hypoalbuminemia (n=4), fatigue (n=3), fever (n=2), abdominal discomfort (n=2), osteolytic lesions (n=2), dizziness (n=1), skin flushing (n=1), and weight loss (n=1). Splenomegaly and lymphadenopathy were noted in six and three patients, respectively. Six patients were strongly positive for CD117, five were positive for CD30 and CD25, and four were positive for CD2. Four patients had a normal karyotype and two patients had an abnormal karyotype. Gene mutations were detected in 4/6 cases. The median serum tryptase level was 24.9 (range: 20.1-171.9) μg/L. Two patients were treated with venetoclax and azacitidine for induction (one patient achieved partial remission by combination with afatinib, while there was no remission after combination with dasatinib in the other patient). Two patients did not achieve complete remission despite treatment with cladribine and imatinib, respectively. One patient treated with interferon combined with glucocorticoids was lost to follow-up, and one patient abandoned treatment. The follow-up time ranged from 1.1 to 21.7 months. Three patients died and two survived. Overall, MCL is a rare subtype of systemic mastocytosis with heterogeneous clinical course, and these patients have poor outcome. A better understanding of the clinical characteristics, treatment, and prognosis of MCL is urgently needed.
